Since the approval of the first biotherapeutic protein produced from CHO cells in 1987, researchers have been studying how to improve protein titer and product quality, mainly through cell line development and bioprocess optimization. With recent advances in genetic editing methods (CRISPR/Cas systems) together with large scale systems biology data, further improvements have been made. Here we outline recent progress in protein production from CHO cells through genetic editing and look to the future of improvements through synthetic biology approaches. We describe new work in the expansion of the genetic parts toolkit, including novel promoters, terminators, transcription factors, and genetic circuits, and how these synthetic parts will be used synergistically to continue improvements to protein production.

自1987年首个从CHO细胞产生的生物治疗性蛋白质获批以来，研究人员一直在研究如何通过细胞系开发和生物工艺优化来提高蛋白质效价和产品质量。随着基因编辑方法（CRISPR / Cas系统）的最新进展以及大规模系统生物学数据的发展，已经进行了进一步的改进。在这里，我们概述了通过基因编辑从CHO细胞生产蛋白质的最新进展，并展望了通过合成生物学方法改进的未来。我们描述了遗传部分工具包扩展中的新工作，包括新型启动子，终止子，转录因子和遗传电路，以及如何协同使用这些合成部分来继续改善蛋白质生产。